FDA DEVICE FACTS
NeoLSD MSMS Kit
Perkinelmer, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The NeoLSD MSMS Kit is intended for the quantitative measurement of the activity of the enzymes acid‐β‐ glucocerebrosidase (ABG), acid‐sphingomyelinase (ASM), acid‐α‐glucosidase (GAA), β‐galactocerebrosidase (GALC), α‐ galactosidase A (GLA) and α‐L‐iduronidase (IDUA) in dried blood spots (DBS) from newborn babies. The analysis of the enzymatic activity is intended as an aid in screening newborns for the following lysosomal storage disorders (LSD) respectively; Gaucher Disease, Niemann‐Pick A/B Disease, Pompe Disease, Krabbe Disease, Fabry Disease, and Mucopolysaccharidosis Type I Disease. Same Test Methodology Quantitative mass spectrometric enzymatic activity assay Same Instrument / Software Platform PerkinElmer QSight 210MD SMS Screening System: CTC PAL RSI Sample Manager, Spark Holland SPH1240 Binary Pump. Instrument Software: Simplicity, Data Processing software and with the PerkinElmer MSMS Workstation Software Waters Acquity TQD instrument with MassLynx v4.1 firmware, with Waters 1525 sample pump, with Waters 2777c autosampler, with Waters NeoLynx v4.1 software and with the PerkinElmer MSMS Workstation Software Sample Type Punch from dried blood spot specimen Same Reportable Range (µmol/L/h) IDUA: 0.19 – 22.3 GAA: 0.31 – 25.3 ABG: 0.79 – 20.0 GLA: 0.80 – 20.4 ASM: 0.16 – 13.8 GALC: 0.20 – 7.75 IDUA: 0.34 – 17.2 GAA: 0.44 – 24.2 ABG: 0.69 – 20.1 GLA: 0.97 – 20.9 ASM: 0.90 – 20.5 GALC: 0.63 – 6.3 Lower Limits of Measure (µmol/L/h) IDUA: LoB=0.044, LoD=0.13, LoQ=0.19 GAA: LoB=0.080, LoD=0.31, LoQ=0.31 ABG: LoB=0.114, LoD=0.79, LoQ=0.79 GLA: LoB=0.519, LoD=0.80, LoQ=0.80 ASM: LoB=0.046, LoD=0.16, LoQ=0.16 GALC: LoB=0.120, LoD=0.20, LoQ=0.20 IDUA: LoB=0.059, LoD=0.24, LoQ=0.34 GAA: LoB=0.073, LoD=0.39, LoQ=0.44 ABG: LoB=0.165, LoD=0.63, LoQ=0.69 GLA: LoB=0.476, LoD=0.97, LoQ=0.97 ASM: LoB=0.110, LoD=0.27, LoQ=0.90 GALC: LoB=0.106, LoD=0.34, LoQ=0.63 NeoLSD MSMS Kit with QSight
Calibrators / Standards Molecular Weights & Concentrations of Internal Standards: IDUA: 430.26 / 15.0 μM GAA: 502.32 / 24.0 μM ABG: 390.38 / 20.0 μM GLA: 488.31 / 24.0 μM ASM: 404.40 / 15.0 μM GALC: 416.40 / 10.0 μM Same Controls 3 levels of control material, human blood based Same Expected Values (µmol/L/h) N 0.1% 0.2% 0.3% 2.5% 97.5% N 0.1% 0.2% 0.3% 2.5% 97.5% IDUA 2488 1.36 1.51 1.86 3.31 12.55 IDUA 5041 2.06 2.55 2.62 3.82 13.2 GAA 2488 2.32 2.54 2.79 4.23 19.55 GAA 5041 2.33 2.69 2.92 4.28 17.5 ABG 2488 1.40 1.78 1.96 3.66 18.95 ABG 5041 2.85 3.16 3.33 4.74 20.1 GLA 2488 3.83 4.74 5.44 7.59 41.99 GLA 5041 3.04 3.37 3.62 4.81 25.8 ASM 2488 1.32 1.43 1.57 2.32 8.01 ASM 5041 2.12 2.21 2.37 3.15 12.9 GALC 2488 0.80 1.01 1.07 1.62 14.90 GALC 5041 0.43 0.52 0.56 0.95 9.34 Precision Sample Activity Range Sample CV% Range Sample Activity Range Sample CV% Range
IDUA 0.76-16.4 8.9%-15.8% IDUA 0.92-15.7 8.7%-18.7% GAA 0.95-24.7 7.3%-12.8% GAA 1.29 – 22.4 6.9%-16.7% ABG 1.05-14.7 13.9%-22.8% ABG 1.15-19.3 12.5%-23.2% GLA 1.03-17.6 7.3%-16.1% GLA 1.23-19.3 9.1%-16.1% ASM 0.56-12.2 8.1%-14.5% ASM 0.92-21.5 10.4%-16.7% GALC 0.27-7.75 6.4%-13.4% GALC 0.45-5.58 11.4%-22.7%
Summary of Studies:
Precision:
The NeoLSD kit precision was determined based on the recommendations of the CLSI guideline EP5-A2 and presented in the tables below. The variation of the NeoLSD MSMS kit is based on 108 determinations: 54 plates measured over 22 working days, each plate having 2 replicates per sample. The samples were measured on 3 QSight systems using 3 kit lots. NeoLSD MSMS Kit with QSight
NeoLSD QSight 22-day precision results. ABG n Mean Repeatability Within-lab Between-lot Total variation µmol/L/h SD CV% SD CV% SD CV% SD CV% 1 108 1.05 0.11 10.7 0.24 22.7 0.02 2.4 0.24 22.8 2 108 2.33 0.30 13.0 0.38 16.5 0.11 4.8 0.40 17.2 3 108 6.56 0.71 10.8 0.93 14.1 0.19 2.8 0.95 14.4 4 108 13.0 1.21 9.30 1.73 13.3 0.50 3.9 1.80 13.9 5 108 14.7 2.35 15.9 2.97 20.2 0.29 2.0 2.99 20.3
ASM n Mean Repeatability Within-lab Between-lot Total variation µmol/L/h SD CV% SD CV% SD CV% SD CV% 1 108 0.56 0.06 10.0 0.08 14.0 0.02 3.9 0.08 14.5 2 108 1.12 0.09 8.1 0.11 9.6 0.05 4.1 0.12 10.4 3 108 3.47 0.24 6.9 0.27 7.7 0.09 2.5 0.28 8.1 4 108 7.40 0.71 9.6 0.83 11.2 0.25 3.3 0.86 11.7 5 108 12.2 1.13 9.3 1.32 10.9 0.40 3.3 1.38 11.4
GALC n Mean Repeatability Within-lab Between-lot Total variation µmol/L/h SD CV% SD CV% SD CV% SD CV% 1 108 0.27 0.03 10.1 0.04 13.2 0.01 2.1 0.04 13.4 2 108 0.56 0.05 8.3 0.07 12.6 0.02 3.6 0.07 13.1 3 108 2.58 0.18 7.1 0.19 7.3 0.02 0.8 0.19 7.4 4 108 4.74 0.24 5.1 0.30 6.4 0.03 0.6 0.30 6.4 5 108 7.75 0.78 10.0 0.82 10.5 0.34 4.4 0.89 11.4
IDUA n Mean Repeatability Within-lab Between-lot Total variation µmol/L/h SD CV% SD CV% SD CV% SD CV% 1 108 0.76 0.11 15.1 0.12 15.6 0.02 2.3 0.12 15.8 2 108 1.33 0.12 9.1 0.18 13.5 0.03 2.4 0.18 13.7 3 108 2.71 0.20 7.2 0.25 9.2 0.09 3.3 0.26 9.7 4 108 7.75 0.55 7.0 0.69 8.9 0.04 0.5 0.69 8.9 5 108 16.4 1.78 10.8 2.01 12.2 0.34 2.1 2.04 12.4 NeoLSD MSMS Kit with QSight
GLA n Mean Repeatability Within-lab Between-lot Total variation µmol/L/h SD CV% SD CV% SD CV% SD CV% 1 108 1.03 0.11 10.7 0.16 15.9 0.03 2.6 0.17 16.1 2 108 2.46 0.19 7.5 0.26 10.4 0.04 1.7 0.26 10.5 3 108 6.44 0.49 7.6 0.64 9.9 0.01 0.2 0.64 9.9 4 108 12.2 0.58 4.8 0.95 7.8 0.20 1.6 0.97 7.9 5 108 17.6 1.15 6.5 1.27 7.2 0.15 0.8 1.28 7.3
GAA n Mean Repeatability Within-lab Between-lot Total variation µmol/L/h SD CV% SD CV% SD CV% SD CV% 1 108 0.95 0.08 8.4 0.12 12.7 0.02 1.7 0.12 12.8 2 108 2.80 0.22 7.8 0.24 8.5 0.05 1.7 0.24 8.7 3 108 8.01 0.55 6.9 0.58 7.2 0.11 1.4 0.59 7.3 4 108 17.1 1.76 10.3 1.95 11.4 0.29 1.7 1.97 11.5 5 108 24.7 1.54 6.2 1.81 7.3 0.23 0.9 1.82 7.4
Limit of Blank, Detection and Quantification:
The limits of blank and detection were determined according to the CLSI guideline EP17-A2 and presented in the table below. The limit of blank (LoB) for the NeoLSD MSMS kit is defined as the 95th percentile of a distribution of blank samples determine with 73 determinations. The limit of detection (LoD) of the kit is based on 75 determinations done with low level samples for the QSight 210 MD Screening System.
NeoLSD limit of blank (LoB) and limit of detection (LoD) with QSight. Enzyme LoB LoD ABG 0.114 0.79 ASM 0.046 0.16 GALC 0.120 0.20 IDUA 0.044 0.13 GLA 0.519 0.80 GAA 0.080 0.31 NeoLSD MSMS Kit with QSight
The Limit of Quantitation (LoQ) is defined as the lowest activity fulfilling the total CV% requirement of the assay. For ABG, GLA and IDUA the CV% requirement is <40%. For ASM and GAA <30% and for GALC <50%. If the imprecision criterion was met for activities below LoD, the LoQ was set to be equal to the LoD. The table shows the LoQ results and imprecision observed at these activities:
NeoLSD Limit of Quantitation
Enzyme QSight LoQ (µmol/L/h) ABG 0.79 ASM 0.16 GALC 0.20 IDUA 0.19 GLA 0.80 GAA 0.31
Linearity:
Linearity was determined in accordance with CLSI guideline EP06-A. The data fulfills the acceptance criteria of the study for the PerkinElmer QSight 210 MD Screening System. The linear range for NeoLSD MSMS kit using the QSight is summarized in below.
NeoLSD linear range
Enzyme QSight Linear Range Lower Limit (mol/L/h) Linear Range Upper Limit (mol/L/h) ABG 0.39 20.0 ASM 0.09 13.8 GALC 0.18 7.75 IDUA 0.08 22.3 GLA 0.60 20.4 GAA 0.11 25.3
Interference: Refer to the kit insert for interference information. NeoLSD MSMS Kit with QSight
Screening Performance:
The screening performance of the NeoLSD MSMS kit on QSight and Waters Acquity TQD was compared in a clinical study at US newborn screening laboratory (Site A). In the study 2489 routine newborn samples were tested. Samples tested were from newborns ≤ 48 hours old. The study population was enriched with 12 archived confirmed LSD positive newborn DBS specimens.
The initial cut -off values were based on a percentage of population median activity. The retest cut -off values were set 5% lower from the initial cut-off percentage. The cut-off percentages were applied to daily medians established based on the initial routine sample results for the day. The initial and retest cut-off percentages used in the study are shown below. The final results for the screening performance including confirmed positive specimens are presented below. Two retrospective confirmed positive Krabbe specimens and one routine specimen were categorized as “invalid result”. In routine newborn screening, if a specimen result is categorized as invalid result, a new dried bloodspot specimen should be obtained, and retesting performed using age -specific cut -off values. Invalid results are excluded from the tabulations.
Descriptive statistics for the US Site A.
QSight
Initial cut-off
Retest cut-off
Enzyme
n Enzyme activity (mol/L/h)
Range*
Mean
Median Lower percentiles 0.1% 0.2% 0.3% ABG 2489 1.06 – 102 9.47 8.83 1.40 1.78 1.96 25% 20% ASM 2489 1.09 – 23.7 4.55 4.30 1.32 1.43 1.57 35% 30% GALC 2489 0.48 – 50.0 5.57 4.70 0.80 1.01 1.07 25% 20% IDUA 2489 0.34 – 21.0 7.30 7.05 1.36 1.51 1.86 25% 20% GLA 2489 2.21 – 133 17.5 15.3 3.83 4.74 5.44 35% 30% GAA 2489 1.87 – 31.8 10.1 9.53 2.32 2.54 2.79 25% 20%
TQD
Initial cut-off
Retest cut-off
Enzyme
n Enzyme activity (mol/L/h)
Range*
Mean
Median Lower percentiles 0.1% 0.2% 0.3% ABG 2489 1.09 – 104 9.17 8.50 1.36 1.70 1.88 25% 20% ASM 2489 1.11 – 24.2 4.63 4.39 1.36 1.43 1.60 35% 30% GALC 2489 0.43 – 47.0 5.08 4.25 0.68 0.85 0.92 25% 20% IDUA 2489 0.32 – 21.3 7.24 6.99 1.34 1.44 1.83 25% 20% GLA 2489 1.84 – 144 16.9 14.6 3.64 4.27 4.79 35% 30% GAA 2489 1.92 – 35.6 10.9 10.2 2.40 2.65 2.88 25% 20% * Some results were outside the measuring range and cannot be considered accurate (see section “REPORTING RESULTS”). NeoLSD MSMS Kit with QSight
Screening performance using percentage of daily median cut-off (Invalid results and samples with no repeat result excluded).
Gaucher (ABG) TQD Screening Positive Screening Negative Total
QSight Screening Positive 3* 0 3 Screening Negative 0 2487 2487 Total 3 2487 2490 *Includes 2 retrospective confirmed positive samples
Niemann-Pick A/B (ASM) TQD Screening Positive Screening Negative Total
QSight Screening Positive 2* 0 2 Screening Negative 0 2488 2488 Total 2 2488 2490 *Includes 1 retrospective confirmed positive sample
Krabbe (GALC) TQD Screening Positive Screening Negative Total
QSight Screening Positive 4* 0 4 Screening Negative 0 2486 2486 Total 4 2486 2490 *Includes 1 retrospective confirmed positive sample
MPS I (IDUA) TQD Screening Positive Screening Negative Total
QSight Screening Positive 6* 0 6 Screening Negative 0 2484 2484 Total 6 2484 2490 *Includes 1 retrospective confirmed positive sample NeoLSD MSMS Kit with QSight
Fabry (GLA) TQD Screening Positive Screening Negative Total
QSight Screening Positive 6* 0 6 Screening Negative 0 2484** 2484 Total 6 2484 2490 * Includes 2 retrospective confirmed positive samples **Includes 2 retrospective confirmed positive female samples
Pompe (GAA) TQD Screening Positive Screening Negative Total
QSight Screening Positive 1* 0 1 Screening Negative 0 2489 2489 Total 1 2489 2490 *Includes 1 retrospective confirmed positive sample
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。